JAK/STAT in leukemia: a clinical update

• Published in: Molecular cancer Vol. 23; no. 1; pp. 25 - 12
• Main Authors: Liang, Dong, Wang, Qiaoli, Zhang, Wenbiao, Tang, Hailin, Song, Cailu, Yan, Zhimin, Liang, Yang, Wang, Hua
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.01.2024; BioMed Central; BMC
• Subjects: Antimitotic agents; Antineoplastic agents; Cell differentiation; Cell division; Cellular signal transduction; Clinical trials; Control systems; Cytokines; Development and progression; DNA methylation; Enzyme inhibitors; Genes; Humans; JAK/STAT inhibitors; JAK/STAT signaling pathway; Janus kinase; Janus Kinases - genetics; Janus Kinases - metabolism; Kinases; Leukemia; Lymphocytes; Mutation; Myeloproliferative Disorders - drug therapy; Myeloproliferative Disorders - genetics; Pathogenesis; Patient compliance; Phosphorylation; Proteins; Signal Transduction; STAT Transcription Factors - genetics; STAT Transcription Factors - metabolism; Leukemia; JAK/STAT signaling pathway; JAK/STAT inhibitors

Over the past three decades, considerable efforts have been expended on understanding the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in leukemia, following the identification of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs). The aim of...